Autolus Therapeutics reported a strong launch of Obe-cel in Q3 2025, achieving $21.1 million in net sales, with significant market access and operational stability enhancing growth prospects.

• Q3 2025 net sales for Obe-cel reached $21.1 million, bringing total sales for the first nine months to $51 million.
• The company successfully authorized 60 treatment centers in the U.S., exceeding its initial target for the year.
• Patient access achieved for over 90% of U.S. covered lives, supporting high manufacturing success rates above 90%.
• Growth potential in the CAR T market appears robust, with current market share in active centers estimated at 20%.
• New leadership appointments bolster operational efficiency and strategic direction moving forward.